Other studies have importantly demonstrated that NfL blood levels increase prior to the clinical manifestation of ALS [289–291], suggesting that NfL are valuable biomarkers especially in the earliest phases of the disease and to monitor phenoconversion. Here, NEFL is linked to amyotrophic lateral sclerosis.